CHICAGO — The free market, not government, should drive the pricing and delivery of health care, Sen. Rand Paul, MD, said at the American Academy of Ophthalmology meeting here.The Affordable Care Act does not allow patients to freely choose health insurance or health care services in a free-market economy, according to Paul (R-Ky.).
CHICAGO — One- and 2-year follow-up data indicate expected preservation of visual acuity with relatively few injections of ranibizumab in patients with neovascular age-related macular degeneration, a speaker here said.Giving results from the second interim analysis of the LUMINOUS study, Paul Mitchell, MD, PhD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting that patients in the study represented a more diverse demographic population than patients in other pivotal trials of Lucentis (ranibizumab, Genentech) and, therefore, are more representative of real-world patients.
CHICAGO — Intracameral antibiotics may be the future for endophthalmitis prophylaxis, but further research is needed, a speaker said here.“It is controversial; it is difficult to do a large-scale study appropriately because of the low rate of infection, as well as multiple different variables that could be reintroduced,” Francis S. Mah, MD, said at Cornea Subspecialty Day preceding the American Academy of Ophthalmology meeting.
Before recent changes in estate laws, it was common for attorneys, financial planners and insurance agents to recommend purchasing life insurance — commonly called survivorship life — in an irrevocable trust designed to provide liquidity at the death of yourself and your spouse. That was then. This is now.Today, more taxpayers, i.e., those with combined estates less than $10,600,000, no longer have to worry about the big slice of taxes on your accumulated assets when you and your spouse pass away. The question is then — why keep the life (Read more...)
CHICAGO — The cystoid macular edema-free interval in patients with non-ischemic central retinal vein occlusion previously treated with ranibizumab or bevacizumab is increased with use of aflibercept, according to a speaker here.Presenting the initial results of the Newton trial, Rahul N. Khurana, MD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting that switching to Eylea (aflibercept, Regeneron) may increase the treatment interval in patients with this disease.
CHICAGO — Prophylactic follow-up treatment with additional povidone-iodine and amphotericin B after Boston type 1 keratoprosthesis implantation significantly reduced the rate of postoperative infections, according to a speaker here.“The purpose of our study was to compare the incidence of postoperative infection in those treated with just topical antibacterials vs. those treated with povidone-iodine plus or minus the amphotericin B,” Jeffery D. Welder, MD, said at the American Academy of Ophthalmology meeting.